Akebia Therapeutics
AKBA
132 hedge funds and large institutions have $470M invested in Akebia Therapeutics in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 18 closing their positions.
111% more call options, than puts
Call options by funds: $391K | Put options by funds: $185K
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
61% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 33
11% more funds holding
Funds holding: 119 → 132 (+13)
7.31% more ownership
Funds ownership: 63.98% → 71.29% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $593M → $470M (-$123M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$9.39M |
| 2 |
Renaissance Technologies
New York
|
+$6.64M |
| 3 |
PA
Perceptive Advisors
New York
|
+$5.93M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.6M |
| 5 |
JP Morgan Chase
New York
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.48M |
| 2 |
First Manhattan
New York
|
-$5.76M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$5.43M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.7M |
| 5 |
Two Sigma Investments
New York
|
-$3.04M |
AKBA Hedge Fund Activity: Q4 2017 in Review
132 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2017, worth a combined $470M — down 21% from $593M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new AKBA positions and 18 closed out — a net gain of 13 holders — while 53 added to existing stakes and 33 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $9.39M. The largest seller was Invesco, cutting an estimated $6.48M.
- 132 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2017, up from 119 in Q3 2017.
- Funds reported $470M of Akebia Therapeutics stock for Q4 2017, down 21% quarter-over-quarter.
- 31 funds opened new Akebia Therapeutics positions in Q4 2017 and 18 closed out, a net change of +13 holders.
- The largest Akebia Therapeutics buyer in Q4 2017 was Nantahala Capital Management, an estimated $9.39M added.
- The largest Akebia Therapeutics seller in Q4 2017 was Invesco, an estimated $6.48M sold.
Based on aggregated 13F filings for Q4 2017.